VO-OHPic
VO-OHPic is a reversible, noncompetitive and selective PTEN inhibitor with an IC50 of 46 nM. VO-OHPic attenuates apoptosis, adverse cardiac remodeling, and pro-inflammatory M1 macrophages in doxorubicin-induced cardiomyopathy. VO-OHPic inhibits autophagy[1][2][3].
Product Specifications
CAS Number
675848-25-6
UNSPSC
12352005
Target
Apoptosis; Autophagy; PTEN
Type
Reference compound
Related Pathways
Apoptosis; Autophagy; PI3K/Akt/mTOR
Applications
COVID-19-immunoregulation
Field of Research
Cancer; Metabolic Disease; Inflammation/Immunology; Cardiovascular Disease
Assay Protocol
https://www.medchemexpress.com/vo-ohpic.html
Solubility
10 mM in DMSO
Smiles
[OH2][V+2]([N]1=CC=CC(O)=C1C2=O)([O-]2)([O-]C3=CC=CN=C3C4=O)([O-]4)=O.[H+]
Molecular Formula
C12H10N2O8V
Molecular Weight
361.16
References & Citations
[1]Mak LH, et al. Characterisation of the PTEN inhibitor VO-OHpic. J Chem Biol. 2010 Oct;3 (4) :157-63. doi: 10.1007/s12154-010-0041-7. Epub 2010 Jun 4.|[2]Johnson TA, et al. PTEN inhibitor VO-OHpic attenuates inflammatory M1 macrophages and cardiac remodeling in doxorubicin-induced cardiomyopathy. Am J Physiol Heart Circ Physiol. 2018 Nov 1;315 (5) :H1236-H1249.|[3]Wang W, et al. PTEN inhibitor VO-OHpic suppresses TSC2-/- MEFs proliferation by excessively inhibiting autophagy via the PTEN/PRAS40 pathway. Exp Ther Med. 2020 Jun;19 (6) :3565-3570.
Shipping Conditions
Room temperature
Scientific Category
Reference compound1
Clinical Information
No Development Reported
Citation 01
Cell Death Dis. 2025 Aug 7;16 (1) :595.|J Nanobiotechnology. 2025 May 25;23 (1) :376.|Phytomedicine. 2023 Dec:121:155117.|SSRN. 2023 Jul 17.|Biochem Pharmacol. 2019 Oct:168:82-90.|Biochem Pharmacol. 2020 Jan;171:113715.|Biochim Biophys Acta Mol Basis Dis. 2022 Jan 1;1868 (1) :166292.|BMC Cancer. 2019 Apr 25;19 (1) :391.|Bone Res. 2018 Nov 10;6:32.|Cancer Med. 2019 Aug;8 (9) :4265-4277.|Cell Biol Toxicol. 2025 Feb 27;41 (1) :53.|Cell Death Dis. 2019 May; 10 (5) : 329.|Cell Stem Cell. 2022 Apr 7;29 (4) :545-558.e13.|Clin Transl Med. 2020 Dec;10 (8) :e240.|Clin Transl Med. 2022 Sep;12 (9) :e1061.|Environ Sci Technol. 2020 Sep 1;54 (17) :10783-10796.|Eur Rev Med Pharmacol Sci. 2019 May;23 (10) :4406-4413.|Funct Integr Genomics. 2024 Apr 3;24 (2) :71.|Int Immunopharmacol. 2022 Feb:103:107840.|Int J Mol Med. 2021 Jun;47 (6) :109.|Int J Mol Sci. 2023 Jun 9;24 (12) :9954.|iScience. 2024 Jun 19;27 (7) :110306.|J Adv Res. 2025 Aug:74:589-607.|J Cell Mol Med. 2019 Nov;23 (11) :7535-7544.|Mol Med Rep. 2018 Dec;18 (6) :5489-5501.|Mol Med Rep. 2022 Jul;26 (1) :246.|Mol Nutr Food Res. 2019 Dec;63 (24) :e1900418.|Mol Vis. 2018 Jul 23:24:485-494.|Redox Biol. 2019 Jan;20:390-401. |Redox Biol. 2024 May 17:73:103200.|Stem Cell Res Ther. 2019 Jul 29;10 (1) :217.|Theranostics. 2019 Jul 9;9 (16) :4764-4778.|Theranostics. 2019 Jul 9;9 (18) :5200-5213.|Transl Psychiatry. 2021 Mar 26;11 (1) :185.
Available Sizes
Frequently Asked Questions
More Discoveries
Explore Other Products
Browse additional items from our catalog
